PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Key Points Pfizer’s earnings and stock price soared in early pandemic days thanks to its coronavirus treatment and ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

You can buy shares of Healthpeak Properties and Pfizer with well less than $100 at the moment. At the moment, anyone with ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and ...